These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 23486454)
1. Point: Impact of prostate-specific antigen velocity on management decisions and recommendations. Loeb S; Carter HB J Natl Compr Canc Netw; 2013 Mar; 11(3):281-5. PubMed ID: 23486454 [TBL] [Abstract][Full Text] [Related]
2. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975 [TBL] [Abstract][Full Text] [Related]
3. Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy. Bryant AK; D'Amico AV; Nguyen PL; Einck JP; Kane CJ; McKay RR; Simpson DR; Mundt AJ; Murphy JD; Rose BS Cancer; 2018 Jul; 124(14):2939-2947. PubMed ID: 29727915 [TBL] [Abstract][Full Text] [Related]
4. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475 [TBL] [Abstract][Full Text] [Related]
5. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men. Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548 [TBL] [Abstract][Full Text] [Related]
6. Population-based study of grade progression in patients who harboured Gleason 3 + 3. Sampurno F; Earnest A; Millar J; Frydenberg M; Murphy D; Delprado W; Evans S World J Urol; 2017 Nov; 35(11):1689-1699. PubMed ID: 28500489 [TBL] [Abstract][Full Text] [Related]
7. Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer. Vickers AJ J Natl Compr Canc Netw; 2013 Mar; 11(3):286-90. PubMed ID: 23486455 [TBL] [Abstract][Full Text] [Related]
9. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Vickers AJ; Gupta A; Savage CJ; Pettersson K; Dahlin A; Bjartell A; Manjer J; Scardino PT; Ulmert D; Lilja H Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):255-61. PubMed ID: 21148123 [TBL] [Abstract][Full Text] [Related]
10. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Lazzeri M; Haese A; de la Taille A; Palou Redorta J; McNicholas T; Lughezzani G; Scattoni V; Bini V; Freschi M; Sussman A; Ghaleh B; Le Corvoisier P; Alberola Bou J; Esquena Fernández S; Graefen M; Guazzoni G Eur Urol; 2013 Jun; 63(6):986-94. PubMed ID: 23375961 [TBL] [Abstract][Full Text] [Related]
11. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334 [TBL] [Abstract][Full Text] [Related]
12. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338 [TBL] [Abstract][Full Text] [Related]
13. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214 [TBL] [Abstract][Full Text] [Related]
14. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Vickers AJ; Cronin AM; Roobol MJ; Savage CJ; Peltola M; Pettersson K; Scardino PT; Schröder FH; Lilja H Clin Cancer Res; 2010 Jun; 16(12):3232-9. PubMed ID: 20400522 [TBL] [Abstract][Full Text] [Related]
15. Active surveillance for prostate cancer: when to recommend delayed intervention. Babaian KN Asian J Androl; 2015; 17(6):885-7; discussion 886-7. PubMed ID: 26178391 [TBL] [Abstract][Full Text] [Related]
16. A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore. Lee A; Lim J; Gao X; Liu L; Chia SJ Asia Pac J Clin Oncol; 2017 Oct; 13(5):e348-e355. PubMed ID: 27641069 [TBL] [Abstract][Full Text] [Related]
17. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698 [TBL] [Abstract][Full Text] [Related]
18. Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer. Sanguedolce F; Falagario UG; Castellan P; Di Nauta M; Silecchia G; Bruno SM; Russo D; Treacy PJ; Tewari AK; Montironi R; Carrieri G; Cormio L Urol Oncol; 2020 Oct; 38(10):793.e19-793.e25. PubMed ID: 32220548 [TBL] [Abstract][Full Text] [Related]
19. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937 [TBL] [Abstract][Full Text] [Related]
20. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. Auvinen A; Rannikko A; Taari K; Kujala P; Mirtti T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Oksala N; Pettersson K; Tammela TL Eur J Epidemiol; 2017 Jun; 32(6):521-527. PubMed ID: 28762124 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]